In some patients, a few days or weeks after recovery from carbon monoxide poisoning, new symptoms develop. These can affect mood, ability to think or remember clearly, and movements. Some people develop movement problems that are similar to Parkinson's disease. This damage to brain tissue is called "encephalopathy," and this study will look at the effect of pressurized oxygen therapy on long term, or chronic, encephalopathy.
Carbon monoxide (CO) poisoning is a leading cause of unintentional poisoning deaths in the United States. After a period of apparent recovery, survivors of acute CO-poisoning can develop a potentially permanent neurologic deterioration (DNS). DNS is a rare, poorly known encephalopathy with a 25-50% prevalence among severely poisoned CO-poisoned patients. Its symptoms and signs range from subtle abnormalities to severe dementia, Parkinsonism, gait disturbances, mutism, and incontinence. Recovery from delayed neuropsychiatric syndrome occurs in 50-75% of patients within 1 year. However, this leaves 25-50% permanently impaired. Hyperbaric oxygen therapy (HBO2) is useful after acute poisoning to reduce the chance of developing DNS. However, appropriate therapy for DNS is widely debated; particularly, the role of hyperbaric oxygen therapy (HBO2) after DNS has developed is controversial. This study proposes to ascertain whether hyperbaric oxygen is efficacious in the treatment of chronic DNS brain injury from carbon monoxide (CO) poisoning. Ten participants suffering from DNS for longer than one year will be recruited to the study, which will be prospective, blinded, sham-controlled and crossover in design. Participants will be divided into two groups of five. One group will receive 40 HBO2 treatments \[100% oxygen at twice normal air pressure (2 ATA)\] followed by 40 sham HBO2 treatments \[air at near normal pressure (1.2 ATA)\]. Treatments will be done once daily for 2 hours, Monday through Friday. Neurological and psychologic assessments will be done prior to starting treatments, after each group of 40 treatments. The second group will be treated similarly except that they will receive sham treatments in the first and oxygen treatments second. In this manner, all participants will act as both experimental and control subject and will receive treatment which we believe is therapeutic.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
see arm descriptions
Short Form (36) Health Survey
is a 36-item, patient-reported survey of patient health
Time frame: 4 months (after 80 treatments)
Updrs part 3 (motor function)
Unified Parkinson Disease Rating Scale
Time frame: 0, 2 and 4 months: (prior to study, after 40 treatments and 80 treatments)
BARS- Brief Ataxia Rating Scale
an assessment of ataxia, 30 point scale with 0 being normal
Time frame: 0, 2 and 4 months: (prior to study, after 40 treatments and 80 treatments)
Fahn-Marsden Dystonia Rating Scale
an assessment of dystonia, 120 point scale with 0 being normal
Time frame: 0, 2 and 4 months: (prior to study, after 40 treatments and 80 treatments)
Physician assessment
an assessment of global function, this is a verbal description not a scale
Time frame: prior to study, after 40 treatments and 80 treatments (0, 2 and 4 months)
The Montreal Cognitive Assessment
a brief cognitive screening tool for Mild Cognitive Impairment
Time frame: 0, 2 and 4 months: (prior to study, after 40 treatments and 80 treatments)
Short Form (36) Health Survey
is a 36-item, patient-reported survey of patient health
Time frame: 0, 2 and 4 months: (prior to study, after 40 treatments and 80 treatments)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.